Note 9 - License Agreements (Details Textual) - USD ($)			1 Months Ended	3 Months Ended					6 Months Ended
	Jan. 07, 2024	Jul. 28, 2023	Dec. 31, 2012	Jun. 30, 2024	Dec. 31, 2023		Sep. 30, 2023	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024	Jan. 31, 2012
Income Tax Expense (Benefit)				$ (328,000)				$ (0)	$ (299,000)	$ (0)
Deferred Revenue, Current				3,373,000	$ 152,000	[1]			3,373,000
Precision BioSciences, Inc. [Member]
Investment Purchased Balance Shares (in shares)	2,920,816
Investment Purchased Balance Price Per Share (in dollars per share)	$ 0.77
L F B License Agreement [Member]
License And Collaboration Agreement, Expenses Incurred									31,000,000
Royalty Expense				7,200,000				1,500,000	12,100,000	$ 2,300,000
Accrued Royalties				7,200,000					7,200,000
L F B License Agreement [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)												15 years
Sublicense Agreement With Ildong Pharmaceutical Co [Member]
Upfront Fee Received From Sub License			$ 2,000,000
Income Tax Expense (Benefit)			300,000
License Revenue				38,000				$ 38,000
Deferred Revenue				200,000	300,000				200,000
Deferred Revenue, Current				200,000	200,000				200,000
Additional Amount Receivable on Achievement of Pre-specified Milestones			$ 5,000,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)			15 years
Commercialization Agreement With Neuraxpharm [Member]
Additional Amount Receivable on Achievement of Pre-specified Milestones		$ 492,500,000
License and Collaboration Agreements, One-time, Non-refundable Payment		$ 140,000,000			$ 140,000,000		$ 140,000,000
Royalty Percentage on Net Product Sales		30.00%
Agreement Buyback Period (Year)		2 years
Commercialization Agreement With Neuraxpharm [Member] | Royalty [Member] | Maximum [Member]
Revenues				$ 100,000					$ 200,000
Briumvi Ublituximab [Member] | Product [Member]
Product Sales, Net Related to Performance Obligations											$ 12,500,000
Precision License Agreement [Member]
License Agreement, Amount Paid Upfront	$ 7,500,000
License Agreement, Amount Paid Upfront, Cash	5,250,000
License Agreement, Amount Paid Upfront, Equity Investment	2,250,000
License Agreement, Deferred Payment	$ 2,500,000
License Agreement, Percentage of Premium on Equity Investment	100.00%
License Agreement, Share Price, Trading Days (Day)	30 days
License Agreement, Additional Milestone Payments	$ 293,000,000
Term After First Commercial Sale (Year)	10 years

[1] Amounts as of December 31, 2023 have been reclassified to conform to current period presentation.